NO20014895D0 - Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate - Google Patents
Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonateInfo
- Publication number
- NO20014895D0 NO20014895D0 NO20014895A NO20014895A NO20014895D0 NO 20014895 D0 NO20014895 D0 NO 20014895D0 NO 20014895 A NO20014895 A NO 20014895A NO 20014895 A NO20014895 A NO 20014895A NO 20014895 D0 NO20014895 D0 NO 20014895D0
- Authority
- NO
- Norway
- Prior art keywords
- bisphosphonate
- additive
- pharmaceutical formulation
- provides increased
- formulation including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9901272A SE9901272D0 (en) | 1999-04-09 | 1999-04-09 | New improved formulation |
PCT/SE2000/000664 WO2000061111A1 (en) | 1999-04-09 | 2000-04-06 | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20014895D0 true NO20014895D0 (en) | 2001-10-08 |
NO20014895L NO20014895L (en) | 2001-12-10 |
Family
ID=20415159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20014895A NO20014895L (en) | 1999-04-09 | 2001-10-08 | Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1171097A1 (en) |
JP (1) | JP2002541185A (en) |
KR (1) | KR20010104389A (en) |
AU (1) | AU4161900A (en) |
CA (1) | CA2364659A1 (en) |
IL (1) | IL145506A0 (en) |
NO (1) | NO20014895L (en) |
NZ (1) | NZ514478A (en) |
SE (1) | SE9901272D0 (en) |
WO (1) | WO2000061111A1 (en) |
ZA (1) | ZA200108260B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
EP1267890A2 (en) * | 2000-04-07 | 2003-01-02 | The Board of Regents of The University of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
MXPA02010740A (en) * | 2000-05-05 | 2003-03-10 | Hoffmann La Roche | Gel like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts. |
CA2438848C (en) | 2001-03-01 | 2011-05-03 | Emisphere Technologies, Inc. | Compositions for delivering bisphosphonates |
WO2003003999A2 (en) * | 2001-07-02 | 2003-01-16 | Elan Corporation, Plc. | Delivery of a bioactive material |
PL399493A1 (en) | 2002-05-10 | 2012-11-05 | F. Hoffmann-La Roche Ag | Bisphosphonic acids for the treatment and prevention of osteoporosis |
ES2291749T5 (en) | 2002-12-20 | 2011-07-21 | F. Hoffmann-La Roche Ag | FORMULATION OF HIGH DOSES OF IBANDRONATO. |
ATE402942T1 (en) * | 2003-01-17 | 2008-08-15 | Teva Pharma | METHOD FOR REDUCING IRON CONTENT IN RISEDRONATE SODIUM |
GB0310919D0 (en) * | 2003-05-13 | 2003-06-18 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
US8637503B2 (en) | 2003-05-16 | 2014-01-28 | Board Of Regents, The University Of Texas System | Phenothiazine enantiomers as agents for the prevention of bone loss |
US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
RU2359678C2 (en) * | 2004-05-24 | 2009-06-27 | Дзе Проктер Энд Гэмбл Компани | Medicinal forms on basis of biphosphonates |
US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
WO2006020009A1 (en) * | 2004-07-23 | 2006-02-23 | The Procter & Gamble Company | Solid oral dosage form of a bisphosphonate containing a chelating agent |
KR100815040B1 (en) * | 2005-01-31 | 2008-03-18 | 주식회사종근당 | Pharmaceutical compositions containing bisphosphonate for improving oral absorption |
NO20053519L (en) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Use of compounds comprising fatty acids |
BRPI0710503A2 (en) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | use of a pharmaceutical composition, pharmaceutical composition, and oral dosage form |
GB0616794D0 (en) | 2006-08-24 | 2006-10-04 | Arrow Int Ltd | Solid dosage form |
KR20110007242A (en) | 2008-05-07 | 2011-01-21 | 메리온 리서치 Ⅲ 리미티드 | Compositions of peptides and processes of preparation thereof |
JP5421366B2 (en) | 2008-07-21 | 2014-02-19 | オトノミ―,インク. | Controlled release otic structure modulating and innate immune system modulating compounds and methods for treatment of otic disorders |
KR101631243B1 (en) * | 2009-05-13 | 2016-06-17 | 신일제약주식회사 | Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same |
ES2650665T3 (en) | 2009-07-31 | 2018-01-19 | Grünenthal GmbH | Crystallization and bioavailability method |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
FR2954320B1 (en) | 2009-12-17 | 2012-06-15 | Cll Pharma | SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
WO2012094598A2 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
KR20120105738A (en) * | 2011-03-16 | 2012-09-26 | 현대약품 주식회사 | An enteric-coated oral formulation |
JP5874545B2 (en) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
CN107205948B (en) | 2015-01-29 | 2021-12-14 | 诺和诺德股份有限公司 | Tablets comprising a GLP-1 agonist and an enteric coating |
WO2017007777A2 (en) * | 2015-07-06 | 2017-01-12 | Zhengxin Dong | NOVEL FORMULATIONS OF PTHrP ANALOGUE |
EP3455229B1 (en) * | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
CN112972400A (en) * | 2021-03-09 | 2021-06-18 | 华侨大学 | Rapidly disintegrable minodronic acid granules and preparation method thereof |
KR20240013402A (en) * | 2022-07-22 | 2024-01-30 | 주식회사 아이큐어비앤피 | Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618259D0 (en) * | 1986-07-25 | 1986-09-03 | Leo Pharm Prod Ltd | Pharmaceutical compositions |
EP0550385A1 (en) * | 1991-12-19 | 1993-07-07 | Ciba-Geigy Ag | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers |
TW237386B (en) * | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
SE501389C2 (en) * | 1992-04-24 | 1995-01-30 | Leiras Oy | Pharmaceutical preparation and process for its preparation |
DE59300688D1 (en) * | 1993-05-15 | 1995-11-02 | Boehringer Mannheim Gmbh | Tablet with improved bioavailability containing dichloromethylene diphosphonic acid as active ingredient. |
IL118422A0 (en) * | 1995-06-02 | 1996-09-12 | Merck & Co Inc | Use of alendronate for the prevention of osteoporosis |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
FI109088B (en) * | 1997-09-19 | 2002-05-31 | Leiras Oy | Tablet and process for its preparation |
SE9703691D0 (en) * | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-04-09 SE SE9901272A patent/SE9901272D0/en unknown
-
2000
- 2000-04-06 AU AU41619/00A patent/AU4161900A/en not_active Abandoned
- 2000-04-06 KR KR1020017012793A patent/KR20010104389A/en not_active Application Discontinuation
- 2000-04-06 IL IL14550600A patent/IL145506A0/en unknown
- 2000-04-06 JP JP2000610444A patent/JP2002541185A/en active Pending
- 2000-04-06 CA CA002364659A patent/CA2364659A1/en not_active Abandoned
- 2000-04-06 NZ NZ514478A patent/NZ514478A/en unknown
- 2000-04-06 WO PCT/SE2000/000664 patent/WO2000061111A1/en active Search and Examination
- 2000-04-06 EP EP00921288A patent/EP1171097A1/en not_active Withdrawn
-
2001
- 2001-10-08 ZA ZA200108260A patent/ZA200108260B/en unknown
- 2001-10-08 NO NO20014895A patent/NO20014895L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU4161900A (en) | 2000-11-14 |
CA2364659A1 (en) | 2000-10-19 |
ZA200108260B (en) | 2003-03-26 |
EP1171097A1 (en) | 2002-01-16 |
WO2000061111A1 (en) | 2000-10-19 |
NZ514478A (en) | 2004-01-30 |
IL145506A0 (en) | 2002-06-30 |
SE9901272D0 (en) | 1999-04-09 |
JP2002541185A (en) | 2002-12-03 |
NO20014895L (en) | 2001-12-10 |
KR20010104389A (en) | 2001-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20014895L (en) | Pharmaceutical formulation including a bisphosphonate and an additive which provides increased adsorption of the bisphosphonate | |
NO20040564L (en) | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient | |
NO20043702L (en) | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient | |
DK1020462T3 (en) | Heterocyclic compounds and anti-tumor agents containing these as active ingredient | |
NO20016277L (en) | Systems and methods for aerolizing pharmaceutical compositions | |
DE69812089D1 (en) | PHARMACEUTICAL OMEPRAZOLE FORMULATION | |
IL166232A0 (en) | Azaindole derivatives and pharmaceutical compositions containing the same | |
NO20033384D0 (en) | Pharmaceutical formulation | |
DK1498411T3 (en) | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | |
NO20033785D0 (en) | Pharmaceutical formulation | |
DK1557415T3 (en) | Heterocyclic compounds and antitumor drugs containing the same as the active ingredient | |
GB0118689D0 (en) | Pharmaceutical formulation | |
NO20035627D0 (en) | Pharmaceutical formulation | |
NO20006646L (en) | Amino acid derivatives and drugs containing the same as active ingredient | |
HUP0303948A2 (en) | Solid orally-dispersible pharmaceutical formulation | |
ID30032A (en) | PHARMACEUTICAL FORMULATION | |
DK0994697T3 (en) | Rapamycin formulations for oral administration | |
AR025867A1 (en) | PHARMACEUTICAL PORTASDORA FORMULATION | |
NO20004816D0 (en) | New pharmaceutical formulation | |
GB0201607D0 (en) | Formulation for the administration of medicinal substances | |
GB0104749D0 (en) | Pharmaceutical formulation | |
NO20041236L (en) | Pharmaceutical Formulation | |
PT102453B (en) | Formulation of a cephalosporinic compound and tablet comprising the said compound and a water-soluble solution | |
SE0101171D0 (en) | Pharmaceutical formulation | |
SE0103565D0 (en) | Pharmaceutical formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |